SCHEMBL30643684

SCHEMBL30643684

CC(C)(C)OC(=O)N1CCC(F)(C#Cc2ccc(-c3ccc(OCc4ccccc4)nc3OCc3ccccc3)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ OPRD1 P41143 1/20 0.42
▸ OPRK1 P41145 1/20 0.42
▸ PRMT5 O14744 5/20 0.42
▸ TACR1 P25103 1/20 0.39
▸ CCNT1 O60563 1/20 0.39
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ CCNA1 P78396 1/20 0.39
▸ GPR119 Q8TDV5 5/20 0.39
▸ STS P08842 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ YAP1 P46937 2/20 0.38
▸ TLR9 Q9NR96 1/20 0.37
▸ TLR7 Q9NYK1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26641237 0.93 PRMT5 (0.39) OPRD1OPRK1PRMT5CCNT1CCNA2
SCHEMBL26641508 0.90 OPRD1 (0.41) OPRD1OPRK1PRMT5TACR1CCNT1
SCHEMBL26641523 0.89 GRM5 (0.37) —
SCHEMBL26641379 0.88 PRMT5 (0.40) OPRD1OPRK1PRMT5TACR1CCNT1
SCHEMBL26641553 0.87 OPRD1 (0.42) OPRD1OPRK1PRMT5TACR1CCNT1
SCHEMBL26641448 0.86 CYP46A1 (0.43) OPRD1OPRK1PRMT5GPR119ACHE
SCHEMBL27039398 0.85 OPRD1 (0.45) OPRD1OPRK1PRMT5TACR1CCNT1
SCHEMBL26641295 0.84 YAP1 (0.38) OPRD1OPRK1PRMT5CCNT1CCNA2
SCHEMBL30643651 0.84 YAP1 (0.38) OPRD1OPRK1PRMT5CCNT1CCNA2
SCHEMBL30830495 0.83 GPR119 (0.47) OPRD1OPRK1PRMT5GPR119ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120092003-A CDK protein degrading agents, pharmaceutical compositions and therapeutic uses 拜欧斯瑞克斯公司 2025-06-03 — — CN disclosed
WO-2023220640-A1 CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2023-11-16 — — WO disclosed
Send feedback